Estrogen receptor beta inhibits transcriptional activity of hypoxia inducible factor-1 through the downregulation of arylhydrocarbon receptor nuclear translocator

Breast Cancer Research

Volumn 13, Issue 2, 2011, Pages

  Lim, Wonchung ^a   Park, Yeomyung ^a   Cho, Jungyoon ^a   Park, Choa ^a   Park, Joonwoo ^a   Park, Young Kwon ^b   Park, Hyunsung ^b   Lee, YoungJoo ^a  

^a Sejong University   (South Korea)

^b University of Seoul   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR BETA; HYPOXIA INDUCIBLE FACTOR 1; HYPOXIA INDUCIBLE FACTOR 1BETA; VASCULOTROPIN; MESSENGER RNA; VASCULOTROPIN A;

ARTICLE; CONTROLLED STUDY; DNA RESPONSIVE ELEMENT; DOWN REGULATION; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; PROTEIN BINDING; PROTEIN FUNCTION; RECEPTOR INTRINSIC ACTIVITY; TRANSCRIPTION REGULATION; UBIQUITINATION; BIOSYNTHESIS; BREAST TUMOR; CELL HYPOXIA; CELL STRAIN HEK293; CHROMATIN IMMUNOPRECIPITATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENETIC TRANSCRIPTION; GENETICS; METABOLISM; METASTASIS; PROMOTER REGION; TRANSCRIPTION INITIATION; TUMOR CELL LINE;

ARYL HYDROCARBON RECEPTOR NUCLEAR TRANSLOCATOR; BREAST NEOPLASMS; CELL HYPOXIA; CELL LINE, TUMOR; CHROMATIN IMMUNOPRECIPITATION; DOWN-REGULATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; ESTROGEN RECEPTOR BETA; FEMALE; HEK293 CELLS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; NEOPLASM METASTASIS; PROMOTER REGIONS, GENETIC; PROTEIN BINDING; RNA, MESSENGER; TRANSCRIPTION, GENETIC; TRANSCRIPTIONAL ACTIVATION; UBIQUITINATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84860389636     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr2854     Document Type: Article

References (58)

1. Hou YF, Yuan ST, Li HC, Wu J, Lu JS, Liu G, Lu LJ, Shen ZZ, Ding J, Shao ZM. ERbeta exerts multiple stimulative effects on human breast carcinoma cells. Oncogene 2004, 23:5799-5806. 10.1038/sj.onc.1207765, 15208676.
2. Rüegg J, Swedenborg E, Wahlström D, Escande A, Balaguer P, Pettersson K, Pongratz I. The transcription factor aryl hydrocarbon receptor nuclear translocator functions as an estrogen receptor beta-selective coactivator, and its recruitment to alternative pathways mediates antiestrogenic effects of dioxin. Mol Endocrinol 2008, 22:304-316.
3. Ali S, Coombes RC. Endocrine-responsive breast cancer and strategies for combating resistance. Nat Rev Cancer 2002, 2:101-112. 10.1038/nrc721, 12635173.
4. Fujita T, Kobayashi Y, Wada O, Tateishi Y, Kitada L, Yamamoto Y, Takashima H, Murayama A, Yano T, Baba T, Kato S, Kawabe Y, Yanagisawa J. Full activation of estrogen receptor alpha activation function-1 induces proliferation of breast cancer cells. J Biol Chem 2003, 278:26704-26714. 10.1074/jbc.M301031200, 12738788.
5. Helguero LA, Faulds MH, Gustafsson JA, Haldosén LA. Estrogen receptors alpha (ERalpha) and beta (ERbeta) differentially regulate proliferation and apoptosis of the normal murine mammary epithelial cell line HC11. Oncogene 2005, 24:6605-6616. 10.1038/sj.onc.1208807, 16007178.
6. Ström A, Hartman J, Foster JS, Kietz S, Wimalasena J, Gustafsson JA. Estrogen receptor beta inhibits 17beta-estradiol-stimulated proliferation of the breast cancer cell line T47D. Proc Natl Acad Sci U S A 2006, 101:1566-1571.
7. Paruthiyil S, Parmar H, Kerekatte V, Cunha GR, Firestone GL, Leitman DC. Estrogen receptor beta inhibits human breast cancer cell proliferation and tumor formation by causing a G2 cell cycle arrest. Cancer Res 2004, 64:423-428. 10.1158/0008-5472.CAN-03-2446, 14729654.
8. Sotoca AM, van den Berg H, Vervoort J, van der Saag P, Ström A, Gustafsson JA, Rietjens I, Murk AJ. Influence of cellular ERalpha/ERbeta ratio on the ERalpha-agonist induced proliferation of human T47D breast cancer cells. Toxicol Sci 2008, 105:303-311. 10.1093/toxsci/kfn141, 2527638, 18644836.
9. Hartman J, Lindberg K, Morani A, Inzunza J, Ström A, Gustafsson JA. Estrogen receptor beta inhibits angiogenesis and growth of T47D breast cancer xenografts. Cancer Res 2006, 66:11207-11213. 10.1158/0008-5472.CAN-06-0017, 17145865.
10. Hartman J, Edvardsson K, Lindberg K, Zhao C, Williams C, Ström A, Gustafsson JA. Tumor repressive functions of estrogen receptor beta in SW480 colon cancer cells. Cancer Res 2009, 69:6100-6106. 10.1158/0008-5472.CAN-09-0506, 19602591.
11. Zhao C, Dahlman-Wright K, Gustafsson JA. Estrogen receptor beta: an overview and update. Nucl Recept Signal 2008, 6:e003. 2254331, 18301783.
12. Zheng X, Linke S, Dias JM, Zheng X, Gradin K, Wallis TP, Hamilton BR, Gustafsson M, Ruas JL, Wilkins S, Bilton RL, Brismar K, Whitelaw ML, Pereira T, Gorman JJ, Ericson J, Peet DJ, Lendahl U, Poellinger L. Interaction with factor inhibiting HIF-1 defines an additional mode of cross-coupling between the Notch and hypoxia signaling pathways. Proc Natl Acad Sci USA 2008, 105:3368-3373. 10.1073/pnas.0711591105, 2265116, 18299578.
13. Harris AL. Hypoxia--a key regulatory factor in tumour growth. Nat Rev Cancer 2002, 2:38-47. 10.1038/nrc704, 11902584.
14. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003, 3:721-732. 10.1038/nrc1187, 13130303.
15. Gordan JD, Simon MC. Hypoxia-inducible factors: central regulators of the tumor phenotype. Curr Opin Genet Dev 2007, 17:71-77. 10.1016/j.gde.2006.12.006, 17208433.
16. Tam BY, Wei K, Rudge JS, Hoffman J, Holash J, Park SK, Yuan J, Hefner C, Chartier C, Lee JS, Jiang S, Niyak NR, Kuypers FA, Ma L, Sundram U, Wu G, Garcia JA, Schrier SL, Maher JJ, Johnson RS, Yancopoulos GD, Mulligan RC, Kuo CJ. VEGF modulates erythropoiesis through regulation of adult hepatic erythropoietin synthesis. Nat Med 2006, 12:793-800. 10.1038/nm1428, 16799557.
17. Yoon D, Pastore YD, Divoky V, Liu E, Mlodnicka AE, Rainey K, Ponka P, Semenza GL, Schumacher A, Prchal JT. Hypoxia-inducible factor-1 deficiency results in dysregulated erythropoiesis signaling and iron homeostasis in mouse development. J Biol Chem 2006, 281:25703-25711. 10.1074/jbc.M602329200, 16787915.
18. Grimm C, Wenzel A, Groszer M, Mayser H, Seeliger M, Samardzija M, Bauer C, Gassmann M, Remé CE. HIF-1-induced erythropoietin in the hypoxic retina protects against light-induced retinal degeneration. Nat Med 2002, 8:718-724. 10.1038/nm723, 12068288.
19. Kallio PJ, Okamoto K, O'Brien S, Carrero P, Makino Y, Tanaka H, Poellinger L. Signal transduction in hypoxic cells: inducible nuclear translocation and recruitment of the CBP/p300 coactivator by the hypoxia-inducible factor-1alpha. EMBO J 1998, 17:6573-6586. 10.1093/emboj/17.22.6573, 1171004, 9822602.
20. Kallio PJ, Pongratz I, Gradin K, McGuire J, Poellinger L. Activation of hypoxia-inducible factor 1alpha: posttranscriptional regulation and conformational change by recruitment of the Arnt transcription factor. Proc Natl Acad Sci USA 1997, 94:5667-5672. 10.1073/pnas.94.11.5667, 20836, 9159130.
21. Brunnberg S, Pettersson K, Rydin E, Matthews J, Hanberg A, Pongratz I. The basic helix-loop-helix-PAS protein ARNT functions as a potent coactivator of estrogen receptor-dependent transcription. Proc Natl Acad Sci USA 2003, 100:6517-6522. 10.1073/pnas.1136688100, 164478, 12754377.
22. Kronenberg S, Esser C, Carlberg C. An aryl hydrocarbon receptor conformation acts as the functional core of nuclear dioxin signaling. Nucleic Acids Res 2000, 28:2286-2291. 10.1093/nar/28.12.2286, 102727, 10871357.
23. Jensen KA, Luu TC, Chan WK. A truncated Ah receptor blocks the hypoxia and estrogen receptor signaling pathways: a viable approach for breast cancer treatment. Mol Pharm 2006, 3:695-703. 10.1021/mp0600438, 2761706, 17140257.
24. Lim W, Cho J, Kwon HY, Park Y, Rhyu MR, Lee Y. Hypoxia-inducible factor 1 alpha activates and is inhibited by unoccupied estrogen receptor beta. FEBS Lett 2009, 583:1314-1318. 10.1016/j.febslet.2009.03.028, 19303878.
25. Mimura J, Fujii-Kuriyama Y. Functional role of AhR in the expression of toxic effects by TCDD. Biochim Biophys Acta 2003, 1619:263-268.
26. Murata T, Shimotohno K. Ubiquitination and proteasome-dependent degradation of human eukaryotic translation initiation factor 4E. J Biol Chem 2006, 281:20788-20800. 10.1074/jbc.M600563200, 16720573.
27. Wenger RH, Stiehl DP, Camenisch G. Integration of oxygen signaling at the consensus HRE. Sci STKE 2005, 2005:re12. 10.1126/stke.3062005re12, 16234508.
28. Coradini D, Pellizzaro C, Speranza A, Daidone MG. Hypoxia and estrogen receptor profile influence the responsiveness of human breast cancer cells to estradiol and antiestrogens. Cell Mol Life Sci 2004, 61:76-82. 10.1007/s00018-003-3324-0, 14704855.
29. Mak P, Leav I, Pursell B, Bae D, Yang X, Taglienti CA, Gouvin LM, Sharma VM, Mercurio AM. ERbeta impedes prostate cancer EMT by destabilizing HIF-1alpha and inhibiting VEGF-mediated snail nuclear localization: implications for Gleason grading. Cancer Cell 2010, 17:319-332. 10.1016/j.ccr.2010.02.030, 20385358.
30. Maltepe E, Schmidt JV, Baunoch D, Bradfield CA, Simon MC. Abnormal angiogenesis and responses to glucose and oxygen deprivation in mice lacking the protein ARNT. Nature 1997, 386:403-407. 10.1038/386403a0, 9121557.
31. Rankin EB, Higgins DF, Walisser JA, Johnson RS, Bradfield CA, Haase VH. Inactivation of the arylhydrocarbon receptor nuclear translocator (Arnt) suppresses von Hippel-Lindau disease-associated vascular tumours in mice. Mol Cell Biol 2005, 25:3163-3172. 10.1128/MCB.25.8.3163-3172.2005, 1069599, 15798202.
32. Tateishi Y, Sonoo R, Sekiya Y, Sunahara N, Kawano M, Wayama M, Hirota R, Kawabe Y, Murayama A, Kato S, Kimura K, Yanagisawa J. Turning off estrogen receptor beta-mediated transcription requires estrogen-dependent receptor proteolysis. Mol Cell Biol 2006, 26:7966-7976. 10.1128/MCB.00713-06, 1636734, 16940184.
33. Choi H, Chun YS, Kim SW, Kim MS, Park JW. Curcumin inhibits hypoxia-inducible factor-1 by degrading aryl hydrocarbon receptor nuclear translocator: a mechanism of tumor growth inhibition. Mol Pharmacol 2006, 70:1664-1671. 10.1124/mol.106.025817, 16880289.
34. Mukundan H, Kanagy NL, Resta TC. 17-beta estradiol attenuates hypoxic induction of HIF-1alpha and erythropoietin in Hep3B cells. J Cardiovasc Pharmacol 2004, 44:93-100. 10.1097/00005344-200407000-00013, 15175563.
35. Earley S, Resta TC. Estradiol attenuates hypoxia-induced pulmonary endothelin-1 gene expression. Am J Physiol Lung Cell Mol Physiol 2002, 283:L86-L93.
36. Crossno JT, Garat CV, Reusch JE, Morris KG, Dempsey EC, McMurtry IF, Stenmark KR, Klemm DJ. Rosiglitazone attenuates hypoxia-induced pulmonary arterial remodeling. Am J Physiol Lung Cell Mol Physiol 2007, 292:L885-L897. 10.1152/ajplung.00258.2006, 17189321.
37. Lee KS, Kim SR, Park SJ, Park HS, Min KH, Jin SM, Lee MK, Kim UH, Lee YC. Peroxisome proliferator activated receptor-gamma modulates reactive oxygen species generation and activation of nuclear factor-kappaB and hypoxia-inducible factor 1alpha in allergic airway disease of mice. J Allergy Clin Immunol 2006, 118:120-127. 10.1016/j.jaci.2006.03.021, 16815147.
38. Wagner AE, Huck G, Stiehl DP, Jelkmann W, Hellwig-Bürgel T. Dexamethasone impairs hypoxia-inducible factor-1 function. Biochem Biophys Res Commun 2008, 372:336-340. 10.1016/j.bbrc.2008.05.061, 18501194.
39. Sandau US, Handa RJ. Glucocorticoids exacerbate hypoxia-induced expression of the pro-apoptotic gene Bnip3 in the developing cortex. Neuroscience 2007, 144:482-494. 10.1016/j.neuroscience.2006.10.003, 1832146, 17110051.
40. Gerstner B, Lee J, Desilva TM, Jensen FE, Volpe JJ, Rosenberg PA. 17beta-estradiol protects against hypoxic/ischemic white matter damage in the neonatal rat brain. J Neurosci Res 2009, 87:2078-2086. 10.1002/jnr.22023, 2770176, 19224575.
41. Lee MY, Lee JH, Han HJ. Estradiol-17beta protects against hypoxia-induced hepatocyte injury through ER-mediated upregulation of Bcl-2 as well as ER-independent antioxidant effects. Cell Res 2008, 18:491-499. 10.1038/cr.2008.42, 18379592.
42. Kodama T, Shimizu N, Yoshikawa N, Makino Y, Ouchida R, Okamoto K, Hisada T, Nakamura H, Morimoto C, Tanaka H. Role of the glucocorticoid receptor for regulation of hypoxia-dependent gene expression. J Biol Chem 2003, 278:33384-33391. 10.1074/jbc.M302581200, 12810720.
43. Park SY, Kim YJ, Gao AC, Mohler JL, Onate SA, Hidalgo AA, Ip C, Park EM, Yoon SY, Park YM. Hypoxia increases androgen receptor activity in prostate cancer cells. Cancer Res 2006, 66:5121-5129. 10.1158/0008-5472.CAN-05-1341, 16707435.
44. Yi JM, Kwon HY, Cho JY, Lee YJ. Estrogen and hypoxia regulate estrogen receptor alpha in a synergistic manner. Biochem Biophys Res Commun 2009, 378:842-846. 10.1016/j.bbrc.2008.11.142, 19084502.
45. Cho J, Kim D, Lee S, Lee Y. Cobalt chloride-induced estrogen receptor alpha down-regulation involves hypoxia-inducible factor-1alpha in MCF-7 human breast cancer cells. Mol Endocrinol 2005, 19:1191-1199. 10.1210/me.2004-0162, 15695373.
46. Cho J, Bahn JJ, Park M, Ahn W, Lee YJ. Hypoxic activation of unoccupied estrogen-receptor-alpha is mediated by hypoxia-inducible factor-1 alpha. J Steroid Biochem Mol Biol 2006, 100:18-23. 10.1016/j.jsbmb.2006.03.002, 16797973.
47. Stoner M, Saville B, Wormke M, Dean D, Burghardt R, Safe S. Hypoxia induces proteasome-dependent degradation of estrogen receptor alpha in ZR-75 breast cancer cells. Mol Endocrinol 2002, 16:2231-2242. 10.1210/me.2001-0347, 12351689.
48. Belanger AJ, Luo Z, Vincent KA, Akita GY, Cheng SH, Gregory RJ, Jiang C. Hypoxia-inducible factor 1 mediates hypoxia-induced cardiomyocyte lipid accumulation by reducing the DNA binding activity of peroxisome proliferator-activated receptor alpha/retinoid X receptor. Biochem Biophys Res Commun 2007, 364:567-572. 10.1016/j.bbrc.2007.10.062, 17963722.
49. Li X, Kimura H, Hirota K, Sugimoto H, Kimura N, Takahashi N, Fujii H, Yoshida H. Hypoxia reduces the expression and anti-inflammatory effects of peroxisome proliferator-activated receptor-gamma in human proximal renal tubular cells. Nephrol Dial Transplant 2007, 22:1041-1051. 10.1093/ndt/gfl766, 17255125.
50. Narravula S, Colgan SP. Hypoxia-inducible factor 1-mediated inhibition of peroxisome proliferator-activated receptor alpha expression during hypoxia. J Immunol 2001, 166:7543-7548.
51. Huss JM, Levy FH, Kelly DP. Hypoxia inhibits the peroxisome proliferator-activated receptor alpha/retinoid X receptor gene regulatory pathway in cardiac myocytes: a mechanism for O2-dependent modulation of mitochondrial fatty acid oxidation. J Biol Chem 2001, 276:27605-27612. 10.1074/jbc.M100277200, 11371554.
52. Leonard MO, Godson C, Brady HR, Taylor CT. Potentiation of glucocorticoid activity in hypoxia through induction of the glucocorticoid receptor. J Immunol 2005, 174:2250-2257.
53. Fan M, Park A, Nephew KP. CHIP (carboxyl terminus of Hsc70-interacting protein) promotes basal and geldanamycin-induced degradation of estrogen receptor-alpha. Mol Endocrinol 2005, 19:2901-2914. 10.1210/me.2005-0111, 16037132.
54. Cvoro A, Tzagarakis-Foster C, Tatomer D, Paruthiyil S, Fox MS, Leitman DC. Distinct roles of unliganded and liganded estrogen receptors in transcriptional repression. Mol Cell 2006, 21:555-564. 10.1016/j.molcel.2006.01.014, 16483936.
55. Maynadier M, Ramirez JM, Cathiard AM, Platet N, Gras D, Gleizes M, Sheikh MS, Nirde P, Garcia M. Unliganded estrogen receptor alpha inhibits breast cancer cell growth through interaction with a cyclin-dependent kinase inhibitor (p21(WAF1)). FASEB J 2008, 22:671-681. 10.1096/fj.07-9322com, 17911387.
56. Lazennec G, Bresson D, Lucas A, Chauveau C, Vignon F. ER beta inhibits proliferation and invasion of breast cancer cells. Endocrinology 2001, 142:4120-4130. 10.1210/en.142.9.4120, 2040491, 11517191.
57. Tremblay A, Tremblay GB, Labrie F, Giguère V. Ligand-independent recruitment of SRC-1 to estrogen receptor beta through phosphorylation of activation function AF-1. Mol Cell 1999, 3:513-519. 10.1016/S1097-2765(00)80479-7, 10230404.
58. Tremblay A, Giguère V. Contribution of steroid receptor coactivator-1 and CREB binding protein in ligand-independent activity of estrogen receptor beta. J Steroid Biochem Mol Biol 2001, 77:19-27. 10.1016/S0960-0760(01)00031-0, 11358671.